Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 21, 2020The Journal of Infectious Diseases

Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

View Full Paper
Ask AI
Bookmark
Share

Authors

KWKristi L. WilliamsABArangassery Rosemary BastianRFRobert Feldman

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Williams et al. (2020) studied this question.

synapsesocial.com/papers/6a1bf5ed1567d2fc4d5f542ahttps://doi.org/10.1093/infdis/jiaa193
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adults 65 Years Old and Older Have Reduced Numbers of Functional Memory T Cells to Respiratory Syncytial Virus Fusion Protein2012 · 116 citations
  2. 2Comparison of the Safety and Immunogenicity of 2 Respiratory Syncytial Virus (RSV) Vaccines— Nonadjuvanted Vaccine or Vaccine Adjuvanted with Alum—Given Concomitantly with Influenza Vaccine to High‐Risk Elderly Individuals2008 · 81 citations
  3. 3Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention2016 · 85 citations
  4. 4Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States2003 · 3,715 citations
  5. 5Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults2005 · 2,272 citations